NovoCure
NVCR
224 hedge funds and large institutions have $1.45B invested in NovoCure in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 78 reducing their positions, and 33 closing their positions.
207% more call options, than puts
Call options by funds: $25.1M | Put options by funds: $8.17M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.52% less ownership
Funds ownership: 86.34% → 85.82% (-0.52%)
5% less funds holding
Funds holding: 236 → 224 (-12)
9% less capital invested
Capital invested by funds: $1.59B → $1.45B (-$140M)
19% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 78
27% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$36.3M |
| 2 |
NA
Nordwand Advisors
Radnor,
Pennsylvania
|
+$27.5M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$19.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
| 5 |
BlackRock
New York
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$68.4M |
| 2 |
Millennium Management
New York
|
-$17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.37M |
| 4 |
Two Sigma Investments
New York
|
-$9.14M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$7.52M |
NVCR Hedge Fund Activity: Q3 2024 in Review
224 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2024, worth a combined $1.45B — down 8.8% from $1.59B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of NVCR and 24 opened new positions — a net loss of 9 holders — while 78 trimmed existing stakes and 63 added.
The largest buyer was Capital World Investors, adding an estimated $36.3M. The largest seller was Capital International Investors, cutting an estimated $68.4M.
- 224 institutional investors held NovoCure (NVCR) as of Q3 2024, down from 236 in Q2 2024.
- Funds reported $1.45B of NovoCure stock for Q3 2024, down 8.8% quarter-over-quarter.
- 24 funds opened new NovoCure positions in Q3 2024 and 33 closed out, a net change of -9 holders.
- The largest NovoCure buyer in Q3 2024 was Capital World Investors, an estimated $36.3M added.
- The largest NovoCure seller in Q3 2024 was Capital International Investors, an estimated $68.4M sold.
Based on aggregated 13F filings for Q3 2024.